Literature DB >> 24733851

Progression-free survival: too much risk, not enough reward?

Brian M Alexander1, Lorenzo Trippa.   

Abstract

Mesh:

Year:  2014        PMID: 24733851      PMCID: PMC3984564          DOI: 10.1093/neuonc/nou041

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  6 in total

1.  Detecting an overall survival benefit that is derived from progression-free survival.

Authors:  Kristine R Broglio; Donald A Berry
Journal:  J Natl Cancer Inst       Date:  2009-11-09       Impact factor: 13.506

2.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

3.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

4.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

5.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

6.  Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.

Authors:  Kelong Han; Melanie Ren; Wolfgang Wick; Lauren Abrey; Asha Das; Jin Jin; David A Reardon
Journal:  Neuro Oncol       Date:  2013-12-12       Impact factor: 12.300

  6 in total
  10 in total

1.  Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials.

Authors:  Lorenzo Trippa; Patrick Y Wen; Giovanni Parmigiani; Donald A Berry; Brian M Alexander
Journal:  Neuro Oncol       Date:  2015-01-07       Impact factor: 12.300

2.  Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.

Authors:  Stuart A Grossman; Karisa C Schreck; Karla Ballman; Brian Alexander
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

Review 3.  Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.

Authors:  Brian M Alexander; Evanthia Galanis; W K Alfred Yung; Karla V Ballman; James M Boyett; Timothy F Cloughesy; John F Degroot; Jason T Huse; Bhupinder Mann; Warren Mason; Ingo K Mellinghoff; Tom Mikkelsen; Paul S Mischel; Brian P O'Neill; Michael D Prados; Jann N Sarkaria; Abdul Tawab-Amiri; Lorenzo Trippa; Xiaobu Ye; Keith L Ligon; Donald A Berry; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2014-08-26       Impact factor: 12.300

4.  The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

Authors:  Alyssa M Vanderbeek; Rifaquat Rahman; Geoffrey Fell; Steffen Ventz; Tianqi Chen; Robert Redd; Giovanni Parmigiani; Timothy F Cloughesy; Patrick Y Wen; Lorenzo Trippa; Brian M Alexander
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

Review 5.  The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology.

Authors:  Daniel N Cagney; Joohee Sul; Raymond Y Huang; Keith L Ligon; Patrick Y Wen; Brian M Alexander
Journal:  Neuro Oncol       Date:  2018-08-02       Impact factor: 12.300

Review 6.  Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?

Authors:  Lidia Gatto; Vincenzo Di Nunno; Enrico Franceschi; Alicia Tosoni; Stefania Bartolini; Alba Ariela Brandes
Journal:  Drugs       Date:  2022-04-09       Impact factor: 9.546

Review 7.  Novel Clinical Trial Designs in Neuro-Oncology.

Authors:  Anurag Saraf; Lorenzo Trippa; Rifaquat Rahman
Journal:  Neurotherapeutics       Date:  2022-08-15       Impact factor: 6.088

8.  Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.

Authors:  Shyam K Tanguturi; Lorenzo Trippa; Shakti H Ramkissoon; Kristine Pelton; David Knoff; David Sandak; Neal I Lindeman; Azra H Ligon; Rameen Beroukhim; Giovanni Parmigiani; Patrick Y Wen; Keith L Ligon; Brian M Alexander
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

9.  Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma.

Authors:  Kelong Han; Melanie Ren; Wolfgang Wick; Lauren Abrey; Asha Das; Jin Jin; David A Reardon
Journal:  Neuro Oncol       Date:  2015-02-26       Impact factor: 12.300

10.  Unbiased estimation for response adaptive clinical trials.

Authors:  Jack Bowden; Lorenzo Trippa
Journal:  Stat Methods Med Res       Date:  2015-08-11       Impact factor: 3.021

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.